Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats newly-diagnosed CD33-positive acute myeloid leukemia (AML). Sold as Mylotarg. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Gemtuzumab Ozogamicin (sold as Mylotarg), first approved Sep 1, 2017, with 1 new use approved and 0 published complete response letters.
First approved: Sep 1, 2017
Applications: 1
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $2.3M
Orphan exclusivity until: Jun 16, 2027
First approved in the EU: Apr 19, 2018
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Treatment of acute myeloid leukemiaWyeth Pharmaceuticals, Inc., a Pfizer Company · designated Nov 24, 1999 · approved Jun 16, 2020 · exclusive to Jun 16, 2027
Approvals in the EU (EMA)
First approved in the EU 8 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA